Latest News Archive

Please select Category, Year, and then Month to display items

Nomination of representative from the Qwaqwa Campus convocation and alumni to the UFS Council

01 October 2019 | Story Nikile Ntsababa (Registrar)

The nomination process for the election of two representatives to serve on the UFS Council was finalised on Tuesday, 17 September 2019 – the closing date for nominations.

Here are the names of the nominees (listed alphabetically):

Representative from the Qwaqwa Campus:
None

Other representative:
Mr Christo Dippenaar
Dr Pieter du Toit
Mr Lefa Mabaso
Dr Walter Matli
Mr Zama Sigwebela

Please note that no nominations were received for representatives from the Qwaqwa Campus. Since this scenario is not legislated in the Statute, Institutional Rules, and Convocation Constitution, the Registrar will, after consultation with the President of the Convocation, open another round of nominations for Qwaqwa representatives to Council (with the closing date 8 October 2019) to ensure that the campus is also represented on Council.

Convocation and Alumni members from the Qwaqwa Campus are therefore given a second opportunity to nominate one representative from among their members for the Qwaqwa Campus. All nominations must reach the office of the Registrar no later than 16:30 on Wednesday, 9 October 2019.

Every nomination form shall be signed by four (4) members of the Convocation and shall contain the written acceptance of the nomination by the nominee under his/her signature as well as an abridged CV and a motivation of more or less 200 words.

Nominations are to be submitted to: email: registrar@ufs.ac.za or delivered by hand to Nikile Ntsababa, Main Building, Room 51, Bloemfontein Campus.

Kindly take note that late or incomplete nominations will not be accepted or considered.

Further information regarding the election process will follow in due course.

News Archive

New research informs improved treatment of brain inflammation

2017-10-13

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish

Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept